


**Product Name** : YL-939  
**Cat. No.** : PC-49555  
**CAS No.** : 3023925-68-7  
**Molecular Formula** : C<sub>25</sub>H<sub>26</sub>N<sub>6</sub>O  
**Molecular Weight** : 426.524  
**Target** : Ferroptosis  
**Solubility** : 10 mM in DMSO



## Biological Activity

YL-939 is a novel non-classical and specific **ferroptosis** inhibitor, targets and binds directly to the **prohibitin 2** (PHB2) protein with K<sub>d</sub> of 3.43 μM in SPR assays.

YL-939 is not an inhibitor of apoptosis, necroptosis, pyroptosis, and cuproptosis. did not show impact on the currently known signal pathways regulating ferroptosis.

YL-939 specifically protected cells from ferroptosis in erastin-induced ferroptosis models (HT1080 and ES-2) with EC<sub>50</sub> of 0.14 and 0.09 μM, respectively.

YL-939 protected PHB2 from the degradation by pronase, but had no effect on the PHB2 isoform PHB1, as well as VDAC1 and VDAC2.

YL-939 treatment dose-dependently up-regulated ferritin protein and the mRNA expression of FTH1 and FTL, similar to the effect of PHB2 knockdown, also dose-dependently reduced the intracellular iron level elevated by erastin treatment, blocked autophagosomes/lysosomes, and hence inhibited ferritinophagy.

YL-939 (3 mg/kg) ameliorated liver damage in an acetaminophen (APAP)-induced acute liver injury model.

## References

Wei Yang, et al. *Nat Commun.* 2022 Dec 3;13(1):7473.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com